This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. A new shot for infants against RSV is in short supply, and U.S. health officials told doctors they should prioritize giving the drug to babies at the highest risk of severe disease. Infants less than 6 months who have chronic lung disease or other underlying conditions should be given priority, the Centers for Disease Control and Prevention told doctors in a Monday evening, Oct. 23, 2023 alert.
RSV, or respiratory syncytial virus, is a common cause of coldlike symptoms that can be dangerous for young children. A seasonal virus, it's beingThe new, one-time shot is a lab-made antibody that helps the immune system fight off the virus. Sold under the brand name Beyfortus, the drug was developed by AstraZeneca and Sanofi.for infants born just before or during the RSV season and for those less than 8 months old before the season starts.
In a recent letter to state immunization managers, the CDC said there would be a pause on orders for the shots made through a program that pays for vaccines for poor and uninsured children. On Monday, the CDC put out a more general alert to U.S. doctors.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WOKVNews - 🏆 247. / 63 Read more »
Source: adndotcom - 🏆 293. / 63 Read more »
CDC Warns of Shortage of RSV Shots to Protect BabiesDemand for a new shot that protects babies against respiratory syncytial virus (RSV) has outpaced supply, prompting U.S. health officials to recommend the doses be saved for high-risk infants. In an alert posted Monday afternoon, the U.S. Centers for Disease Control and...
Source: NEWSMAX - 🏆 16. / 71 Read more »
Source: washingtonpost - 🏆 95. / 72 Read more »
Source: wsfa12news - 🏆 338. / 59 Read more »